AbbVie gets approval for Parkinson’s treatment

SHARE AbbVie gets approval for Parkinson’s treatment

AbbVie Inc. has won approval for a new treatment for patients with advanced Parkinson’s disease.

The North Chicago drugmaker said its drug treatment, Duopa, helps Parkinson’s patient maintain motor control. The company announced Monday the treatment has received approval from the U.S. Food and Drug Administration.

The drug treatment was approved three months ahead of the scheduled review date, Reuters reported. Duopa, which is already available in Canada, is delivered by infusion pump directly to the small intestine.

Abbvie retreats on Gilead, Anthem Deal. Buying Opportunity? [SeekingAlpha.com] Shire to acquire NPS Pharma for $5.2 billion

“There is unmet need for treatment options for patients with advanced Parkinson’s disease. As the disease advances, it can be difficult to control motor features,” said Dr. C. Warren Olanow, a professor at Mount Sinai School of Medicine and lead investigator of the drug trial. “In clinical trials, Duopa was shown to significantly reduce the amount of off time advanced Parkinson’s disease patients experienced.”

Michael Severino, AbbVie executive vice president and chief scientific officer, said the drug’s approval “is another significant milestone for AbbVie’s pipeline.”

“This advancement is important for patients with advanced Parkinson’s disease and their care teams, as it provides a new therapeutic option to help manage motor symptoms,” Severino said in a news release.

The Latest
“These books think the White Sox will fail, and I don’t disagree with them,” says one handicapper.
The federal agency announced last year that it would roll out Direct File in a limited number of states as a test run.
Beloved celebrity owl quickly was embraced by New York City for surviving despite the odds after zoo escape made possible by vandal now blamed for shortening its life.
The expansion would certainly provide more government cash for eligible families, but it complicates things further by creating disincentives to work and rise from poverty, especially as it builds on other existing transfers.
In states where physician-assisted suicide is legal, I cannot help but ask if the people who ended their lives had adequate access to services to make life easier, including hospice and palliative care, a disability advocate writes.